3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Ovarian Neoplasms
2
Melanoma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Laryngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Erdheim-Chester Disease
1
Cholangiocarcinoma
1
Adenocarcinoma, Follicular
1
Interventions
trametinib
3
dabrafenib
3
binimetinib
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Docetaxel
2
Cisplatin
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
tipifarnib
1
sapanisertib
1
romidepsin
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
entrectinib
1
entinostat
1
durvalumab
1
defactinib
1
copanlisib
1
cobimetinib
1
capivasertib
1
cabiralizumab
1
adavosertib
1
X-Rays
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
cobimetinib
×
Head & Neck
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled